SlideShare una empresa de Scribd logo
1 de 34
Descargar para leer sin conexión
PPOS Design
Zhongwen Tang
"One important idea is that science is a means whereby learning is achieved,
not by mere theretical speculation on the one hand, nor by the undirected
accumulation of practical facts on the other, but rather by a motivated
iteration between theory and practice." (George E. P. Box)
Outline
Motivation examples
Selected literature reveiw
PPOS design of a pilot trial
PPOS design of futility IA of a con…rmatory trial
Motivation Example1: Pilot Trial Design
Phase II trial to compare PFS between exp and control
Randomization ratio: 1: 1
Traditional design
– Type I error rate: 0.2
– Power=0.7 to detect a HR=0.75
– Event size: 90
Motivation Example1: Pilot Trial Design
Pilot trial (e.g. phase II) results are usually not the …nal goal.
Pilot trial usually provides evidence to support a Go/No Go decision for a bigger
future (e.g. phase III) trial.
Proposal: design a pilot trial based on predictive probability of success (PPOS) in
future con…rmatory trial.
Motivation Example 2: futility interim of a con…rmatory trial
A phase 3 trial to compare PFS between exp and control arms
Number of events at …nal analysis: 500
Type I error rate (one sided) = 0.025
Question: how to place an non-binding futility IA
Traditional design: beta spending
Proposal: design based on PPOS in the …nal analysis
PPOS is a Variable!!!
Conditional power: probability of observing future statistical signi…cance assuming
the parameter equals a speci…c value
Predictive power: probability of observing future statistical signi…cance assuming
the parameter has a speci…c distribution
Predictive probability of success (PPOS): probability of future success assuming the
parameter has a speci…c distribution
Types of PPOS
Type of data: binary, normal, time to event
Relationship between the trial providing data and the trial to be predicted
– cross trial: using data from one trial to predict another independent trial
– within trial: using IA to predict …nal anlaysis (include IA data)
Relationship between the end point providing information and the end point to be
predicted (Tang, 2015)
– 1:1 Use 1 end point to predict same end point
e.g. use PFS at IA to predict PFS at …nal analysis
– 1:1 Use 1 end point to predict di¤erent end point
e.g. use short term end point in a pilot trial to predict a long term end point in
a con…rmatory trial
Seleted Literature Review
Spiegelhalter et al (1986) compared conditional power and predictive power.
Speigelhalter et al (1986) evaluated sample size using predictive probabilities.
– Predictive probability of success
– Predictive probability of failure
– Predictive probability of non-commitment
Selected Literature Review
Stallard, Whitehead, and Cleall (2005) used Bayesian predictive probability of suc-
cess for a Go/No Go decision to phase III based on data from phase II.
The method predicts the success of OS in the phase 3 trial using response and PFS
data from phase 2 trail.
Selected Literature Review
Lee and Liu (2008) proposed a two-stage Bayesian phase II design based on predic-
tive probability of success for binary end point single arm trial.
The method …nds the cuto¤ for PPOS by minimizing the maximum sample size
(Nmax) while meeting type I error rate and power requirement.
Selected Literature Review
Tang and Dey (2011) in a cross trial setting for time to event end point
– Design criteria: PPOS and false positive rate
– Di¤erence between pilot and con…rmatory trial design are accounted by cross
trial variability
Wang et al (2013) in a cross-trial setting for time to event data
– Prediction of combination treatment e¢ cacy based on single agent data
– Prediction of future trial with di¤erent end point from pilot trial
– PPOS calculated using simulation
Selected Literature Review
Berry (2006) covered many real life application of PPOS
– Monitoring trial: In one Herceptin trial without IA, DSMB requested PPOS and
overode the protocol to terminate the trial.
– Adaptive assignment of patients in dose …nding trials
Brannath et al (2009) used PPOS as a facility for population selection in adaptive
design
– Predictive probability and posterior probability are used for decision making.
– Cuto¤ determined by simulated operation characteristic
Common Issues In Current Practice
Interpretation of PPOS based on point estimate alone
PPOS cuto¤ determined by OC
Mixed use of predictive probability of success and posterior probability of success
Cross Trial PPOS and Pilot Trial Design
Cross Trial PPOS
End point: time to event, same in pilot trial and con…rmatory trial
Parameter of interest: ln (HR)
PPOS: predictive probability of observing a successful HR (e.g. clinical meaningful)
in the future trial given the observed HR in the pilot trial.
^ is the estimated ln (HR)
^j ~N ; 2 = 1= (r (1 r) d)
where r is the randomization ratio, d is the number of events
Cross Trial PPOS
Assume a Gaussian prior ln (HR) = ~N 0; 2
0 = 1= (r (1 r) d0)
^1 is the estimated ln (HR) in a pilot trial
^1j ~N ; 2
1 = 1= (r (1 r) d1)
Cross Trial PPOS
The posterior distribution is
j^1~N ^1 + (1 ) 0; 2
0 (1 ) or
where = 1 +
2
1
2
0
1
=
2
0
2
0+ 2
1
Cross Trial PPOS
^2 is the estimated ln (HR) in future con…rmatory trial
^2j ~N ; 2
2 = 1= (r (1 r) d2)
The predictive distribution of ^2j^1 is
^2j^1~N ^1 + (1 ) 0; 2
0 (1 ) + 2
2
PPOS = (
[ ^1+(1 ) 0]q
2
0(1 )+ 2
2
)
Motivation Exampe 1
Input for PPOS calculation
Prior information
– Non-informative prior: prior variance = in…nity (equivalent to 0 event)
Envisioned phase III (matching pilot design): 500 events
Success criteria: HR 0:75 (clinical meaningful)
PPOS in 2 di¤erent designs
Event size = 90;PPOS = 0:30 if observed HR = 0:846 in phase II
Event size = 40;PPOS = 0:30 if observed HR = 0:889 in phase II
PPOS Credible Interval
The information supporting PPOS calculation is summarized in the posterior dis-
tribution.
(1 =2)100% percentile of PPOS = (
[ =2 100% percentile of j^1]q
2
0(1 )+ 2
2
)
PPOS Decision Rule
f
PPOS(d1; HR1) PPOS1
(1 =2) 100th PPOS percentile (d1; HR1) PPOS2
for No Go decision
PPOS Optimal Design
Finding the optimal design is to …nd the solution to the following equations with respect
to d1 and cuto¤ HR1
f
PPOS(d1; cut:HR1) = PPOS1
(1 =2) 100th PPOS percentile (d1; cut:HR1) = PPOS2
Motivation Example1: PPOS design
f
PPOS(d1; HR1) 30%
80th PPOS percentile (d1; HR1) 60%
for No Go decision
Optimal design: d1 = 86;cuto¤ HR = 0:848
Motivation Example1: PPOS optimal design
Contour lines: black (PPOS), red (80th percentile); Intersection: optimal design
Within Trial PPOS and Futility Interim
Design
Within Trial PPOS
Consider a randomized phase 3 trial wiht time to event end point.
Parameter of interest is log(HR)
PPOS: probability of observing a successful HR at the end of the trial given the
data at interim analysis.
PPOS =
0
@
!1z(t)
!2
=
p
r(1 r)(dmax d)
h
'^(t)+(1 ') 0
i
q
2
0(1 ')+ 2
2
1
A (Tang, 2014)
PPOS Decision Rule
We may mandate that if the following 2 conditions are satis…ed, then futility will be
declared.
f
PPOS PPOS1
(1 =2) 100th PPOS percentile PPOS2
PPOS Optimal Design
Finding the optimal futility interim design is to …nd the solution of the following equations
with respect to timing of the analysis t and cuto¤ HR at IA.
f
PPOS(t; HR:IA) = PPOS1
(1 =2) 100th PPOS percentile (t; HR:IA) = PPOS2
Motivation Example 2
Prior variance = in…nity (equivalent to 0 prior events)
Success criteria: observing clinically meaningful results (HR < 0:75) at …nal analy-
sis
Final analysis at 500 events
Randomization ratio 1:1
Optimal futility interim design
When the following 2 conditions are satis…ed, futility will be declared.
f
PPOS(t; HR:IA) 20%
80th PPOS percentile (t; HR:IA) 40%
Optimal futility IA design:t = 0:511; d1 = 256 and cuto¤ HR at IA to be 0:807
Take home message
The success criteria in PPOS is not restricted to statistical signi…cance.
Interpretation of PPOS should be based on both point estimate and CI.
PPOS designs have intuitive interpretation.
PPOS calculation involves subjective choices.
Some analytical methods have been developed to calculate PPOS and CI.
Reference
Berry D. Bayesian clinical trials. Nature reviews, 2006, 5: 27-36.
Brannath W. Zuber E. Branson M. Bretz F. Gallo P. Posch M and Racine-Poon A.
Con…rmatory adaptive designs with Bayesian decision tools for a targeted therapy in
oncology. Statistics in Medicine, 2009, 28, 1445-1463.
Johns D and Anderson J, Use of predictive probabilities in phase II and phase III clinical
trials. Journal of Biopharmaceutical Statistics. 1999; 9(1): 67-79.
Lee J and Liu D, A predictive probability design for phase II cancer clinical trials. Clinical
Trials. 2008; 5:93-106.
Spiegelhalter, D. J. and Freeman L. S. A predictive approach to selecting the size of a
clinical trial, based on subjective clinical opinion. Statistics Medicin, 5: 1-13, 1986.
Spiegelhalter, D. J., Freedman, L. S., Blackburn, P. R. (1986). Monitoring clinical trials:
conditional or predictive power. Controlled Clinical Trials 7:8–17.
Reference
Stallard N, Whitehead J and Cleall S, Decision-making in a phase II clinical trial: a
new approach combining Bayesian and frequentist concepts. Pharmaceutical Statistics,
2005, 4: 119-128.
Tang, Z. Dey, J. (2011). Bayesian PPOS design for clinical trials. PaSIPHIC anual
meeting.
Tang, Z. (2014). Optimal futility interim design: a predictive probability approach with
time to event ene point. Journal of Biopharmaceutical Statistics. DOI: 10.1080/10543406.201
Tang, Z. (2015). Pilot trial design: a predictive probability of success approach with
time to event end points. Statistical Methods in Medical Research (under review).
Wang, Y. Fu, H. Kulkarni, P. and Kaiser, C. (2013). Evaluating and utilizing probability
of study success in clinical development. Clinical Trials, 10, 407-413.

Más contenido relacionado

La actualidad más candente

03 「重回帰分析」の入門
03 「重回帰分析」の入門03 「重回帰分析」の入門
03 「重回帰分析」の入門Shuhei Ichikawa
 
臨床的有意性の書き方
臨床的有意性の書き方臨床的有意性の書き方
臨床的有意性の書き方Yasuyuki Okumura
 
YamadaiR(Categorical Factor Analysis)
YamadaiR(Categorical Factor Analysis)YamadaiR(Categorical Factor Analysis)
YamadaiR(Categorical Factor Analysis)考司 小杉
 
因果関係を時系列変化で分析
因果関係を時系列変化で分析因果関係を時系列変化で分析
因果関係を時系列変化で分析DaikiNagamine
 
博士論文公聴会スライド
博士論文公聴会スライド博士論文公聴会スライド
博士論文公聴会スライドTeruhiko Takagi
 
20160622 srws第五回risk of biasの評価
20160622 srws第五回risk of biasの評価20160622 srws第五回risk of biasの評価
20160622 srws第五回risk of biasの評価SR WS
 
ProxGen: Adaptive Proximal Gradient Methods for Structured Neural Networks (N...
ProxGen: Adaptive Proximal Gradient Methods for Structured Neural Networks (N...ProxGen: Adaptive Proximal Gradient Methods for Structured Neural Networks (N...
ProxGen: Adaptive Proximal Gradient Methods for Structured Neural Networks (N...Jihun Yun
 
20160713 srws第六回後半、revmanでのメタ・アナリシス・ハンズオン
20160713 srws第六回後半、revmanでのメタ・アナリシス・ハンズオン20160713 srws第六回後半、revmanでのメタ・アナリシス・ハンズオン
20160713 srws第六回後半、revmanでのメタ・アナリシス・ハンズオンSR WS
 
「診断精度研究のメタ分析」の入門
「診断精度研究のメタ分析」の入門「診断精度研究のメタ分析」の入門
「診断精度研究のメタ分析」の入門yokomitsuken5
 
【論文読み会】MAUVE: Measuring the Gap Between Neural Text and Human Text using Dive...
【論文読み会】MAUVE: Measuring the Gap Between Neural Text and Human Text using Dive...【論文読み会】MAUVE: Measuring the Gap Between Neural Text and Human Text using Dive...
【論文読み会】MAUVE: Measuring the Gap Between Neural Text and Human Text using Dive...ARISE analytics
 
201707srws第六回その2メタアナリシス・異質性・出版バイアス
201707srws第六回その2メタアナリシス・異質性・出版バイアス201707srws第六回その2メタアナリシス・異質性・出版バイアス
201707srws第六回その2メタアナリシス・異質性・出版バイアスSR WS
 
Deep learning for molecules, introduction to chainer chemistry
Deep learning for molecules, introduction to chainer chemistryDeep learning for molecules, introduction to chainer chemistry
Deep learning for molecules, introduction to chainer chemistryKenta Oono
 
Computational Motor Control: State Space Models for Motor Adaptation (JAIST s...
Computational Motor Control: State Space Models for Motor Adaptation (JAIST s...Computational Motor Control: State Space Models for Motor Adaptation (JAIST s...
Computational Motor Control: State Space Models for Motor Adaptation (JAIST s...hirokazutanaka
 
量的データの分析・報告で気をつけたいこと
量的データの分析・報告で気をつけたいこと量的データの分析・報告で気をつけたいこと
量的データの分析・報告で気をつけたいことMizumoto Atsushi
 
Implementation of QML @ AWS
Implementation of QML @ AWSImplementation of QML @ AWS
Implementation of QML @ AWSMakotoNegoro
 
患者報告式アウトカム尺度における 臨床的意味のある変化の定め方
患者報告式アウトカム尺度における臨床的意味のある変化の定め方患者報告式アウトカム尺度における臨床的意味のある変化の定め方
患者報告式アウトカム尺度における 臨床的意味のある変化の定め方Yasuyuki Okumura
 
Transformerを用いたAutoEncoderの設計と実験
Transformerを用いたAutoEncoderの設計と実験Transformerを用いたAutoEncoderの設計と実験
Transformerを用いたAutoEncoderの設計と実験myxymyxomatosis
 
それでも私が研究を続ける理由
それでも私が研究を続ける理由それでも私が研究を続ける理由
それでも私が研究を続ける理由Hitomi Yanaka
 

La actualidad más candente (20)

03 「重回帰分析」の入門
03 「重回帰分析」の入門03 「重回帰分析」の入門
03 「重回帰分析」の入門
 
臨床的有意性の書き方
臨床的有意性の書き方臨床的有意性の書き方
臨床的有意性の書き方
 
YamadaiR(Categorical Factor Analysis)
YamadaiR(Categorical Factor Analysis)YamadaiR(Categorical Factor Analysis)
YamadaiR(Categorical Factor Analysis)
 
因果関係を時系列変化で分析
因果関係を時系列変化で分析因果関係を時系列変化で分析
因果関係を時系列変化で分析
 
Maeshori missing
Maeshori missingMaeshori missing
Maeshori missing
 
博士論文公聴会スライド
博士論文公聴会スライド博士論文公聴会スライド
博士論文公聴会スライド
 
GAN0420
GAN0420GAN0420
GAN0420
 
20160622 srws第五回risk of biasの評価
20160622 srws第五回risk of biasの評価20160622 srws第五回risk of biasの評価
20160622 srws第五回risk of biasの評価
 
ProxGen: Adaptive Proximal Gradient Methods for Structured Neural Networks (N...
ProxGen: Adaptive Proximal Gradient Methods for Structured Neural Networks (N...ProxGen: Adaptive Proximal Gradient Methods for Structured Neural Networks (N...
ProxGen: Adaptive Proximal Gradient Methods for Structured Neural Networks (N...
 
20160713 srws第六回後半、revmanでのメタ・アナリシス・ハンズオン
20160713 srws第六回後半、revmanでのメタ・アナリシス・ハンズオン20160713 srws第六回後半、revmanでのメタ・アナリシス・ハンズオン
20160713 srws第六回後半、revmanでのメタ・アナリシス・ハンズオン
 
「診断精度研究のメタ分析」の入門
「診断精度研究のメタ分析」の入門「診断精度研究のメタ分析」の入門
「診断精度研究のメタ分析」の入門
 
【論文読み会】MAUVE: Measuring the Gap Between Neural Text and Human Text using Dive...
【論文読み会】MAUVE: Measuring the Gap Between Neural Text and Human Text using Dive...【論文読み会】MAUVE: Measuring the Gap Between Neural Text and Human Text using Dive...
【論文読み会】MAUVE: Measuring the Gap Between Neural Text and Human Text using Dive...
 
201707srws第六回その2メタアナリシス・異質性・出版バイアス
201707srws第六回その2メタアナリシス・異質性・出版バイアス201707srws第六回その2メタアナリシス・異質性・出版バイアス
201707srws第六回その2メタアナリシス・異質性・出版バイアス
 
Deep learning for molecules, introduction to chainer chemistry
Deep learning for molecules, introduction to chainer chemistryDeep learning for molecules, introduction to chainer chemistry
Deep learning for molecules, introduction to chainer chemistry
 
Computational Motor Control: State Space Models for Motor Adaptation (JAIST s...
Computational Motor Control: State Space Models for Motor Adaptation (JAIST s...Computational Motor Control: State Space Models for Motor Adaptation (JAIST s...
Computational Motor Control: State Space Models for Motor Adaptation (JAIST s...
 
量的データの分析・報告で気をつけたいこと
量的データの分析・報告で気をつけたいこと量的データの分析・報告で気をつけたいこと
量的データの分析・報告で気をつけたいこと
 
Implementation of QML @ AWS
Implementation of QML @ AWSImplementation of QML @ AWS
Implementation of QML @ AWS
 
患者報告式アウトカム尺度における 臨床的意味のある変化の定め方
患者報告式アウトカム尺度における臨床的意味のある変化の定め方患者報告式アウトカム尺度における臨床的意味のある変化の定め方
患者報告式アウトカム尺度における 臨床的意味のある変化の定め方
 
Transformerを用いたAutoEncoderの設計と実験
Transformerを用いたAutoEncoderの設計と実験Transformerを用いたAutoEncoderの設計と実験
Transformerを用いたAutoEncoderの設計と実験
 
それでも私が研究を続ける理由
それでも私が研究を続ける理由それでも私が研究を続ける理由
それでも私が研究を続ける理由
 

Similar a PPOS design

Defensive Efficacy Interim Design
Defensive Efficacy Interim DesignDefensive Efficacy Interim Design
Defensive Efficacy Interim DesignZhongwen Tang
 
Survival Analysis With Generalized Additive Models
Survival Analysis With Generalized Additive ModelsSurvival Analysis With Generalized Additive Models
Survival Analysis With Generalized Additive ModelsChristos Argyropoulos
 
Designing studies with recurrent events | Model choices, pitfalls and group s...
Designing studies with recurrent events | Model choices, pitfalls and group s...Designing studies with recurrent events | Model choices, pitfalls and group s...
Designing studies with recurrent events | Model choices, pitfalls and group s...nQuery
 
Choosing statistical tests
Choosing statistical testsChoosing statistical tests
Choosing statistical testsAkiode Noah
 
An SPRT Procedure for an Ungrouped Data using MMLE Approach
An SPRT Procedure for an Ungrouped Data using MMLE ApproachAn SPRT Procedure for an Ungrouped Data using MMLE Approach
An SPRT Procedure for an Ungrouped Data using MMLE ApproachIOSR Journals
 
Practical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size ChallengesPractical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size ChallengesnQuery
 
An Alternative To Null-Hypothesis Significance Tests
An Alternative To Null-Hypothesis Significance TestsAn Alternative To Null-Hypothesis Significance Tests
An Alternative To Null-Hypothesis Significance TestsSarah Morrow
 
Innovative Sample Size Methods For Clinical Trials
Innovative Sample Size Methods For Clinical Trials Innovative Sample Size Methods For Clinical Trials
Innovative Sample Size Methods For Clinical Trials nQuery
 
Exponential software reliability using SPRT: MLE
Exponential software reliability using SPRT: MLEExponential software reliability using SPRT: MLE
Exponential software reliability using SPRT: MLEIOSR Journals
 
Optimizing Oncology Trial Design FAQs & Common Issues
Optimizing Oncology Trial Design FAQs & Common IssuesOptimizing Oncology Trial Design FAQs & Common Issues
Optimizing Oncology Trial Design FAQs & Common IssuesnQuery
 
Extending A Trial’s Design Case Studies Of Dealing With Study Design Issues
Extending A Trial’s Design Case Studies Of Dealing With Study Design IssuesExtending A Trial’s Design Case Studies Of Dealing With Study Design Issues
Extending A Trial’s Design Case Studies Of Dealing With Study Design IssuesnQuery
 
2020 trends in biostatistics what you should know about study design - slid...
2020 trends in biostatistics   what you should know about study design - slid...2020 trends in biostatistics   what you should know about study design - slid...
2020 trends in biostatistics what you should know about study design - slid...nQuery
 
Analyzing experimental research data
Analyzing experimental research dataAnalyzing experimental research data
Analyzing experimental research dataAtula Ahuja
 
Sudhakar singh meta analysis
Sudhakar singh meta analysisSudhakar singh meta analysis
Sudhakar singh meta analysisSudhakarSingh66
 
Basics statistics
Basics statistics Basics statistics
Basics statistics BITS
 

Similar a PPOS design (20)

Defensive Efficacy Interim Design
Defensive Efficacy Interim DesignDefensive Efficacy Interim Design
Defensive Efficacy Interim Design
 
Survival Analysis With Generalized Additive Models
Survival Analysis With Generalized Additive ModelsSurvival Analysis With Generalized Additive Models
Survival Analysis With Generalized Additive Models
 
Designing studies with recurrent events | Model choices, pitfalls and group s...
Designing studies with recurrent events | Model choices, pitfalls and group s...Designing studies with recurrent events | Model choices, pitfalls and group s...
Designing studies with recurrent events | Model choices, pitfalls and group s...
 
Metaanalysis copy
Metaanalysis    copyMetaanalysis    copy
Metaanalysis copy
 
Choosing statistical tests
Choosing statistical testsChoosing statistical tests
Choosing statistical tests
 
An SPRT Procedure for an Ungrouped Data using MMLE Approach
An SPRT Procedure for an Ungrouped Data using MMLE ApproachAn SPRT Procedure for an Ungrouped Data using MMLE Approach
An SPRT Procedure for an Ungrouped Data using MMLE Approach
 
Practical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size ChallengesPractical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size Challenges
 
Methodology
MethodologyMethodology
Methodology
 
Prague 02.10.2008
Prague 02.10.2008Prague 02.10.2008
Prague 02.10.2008
 
An Alternative To Null-Hypothesis Significance Tests
An Alternative To Null-Hypothesis Significance TestsAn Alternative To Null-Hypothesis Significance Tests
An Alternative To Null-Hypothesis Significance Tests
 
Innovative Sample Size Methods For Clinical Trials
Innovative Sample Size Methods For Clinical Trials Innovative Sample Size Methods For Clinical Trials
Innovative Sample Size Methods For Clinical Trials
 
Exponential software reliability using SPRT: MLE
Exponential software reliability using SPRT: MLEExponential software reliability using SPRT: MLE
Exponential software reliability using SPRT: MLE
 
Optimizing Oncology Trial Design FAQs & Common Issues
Optimizing Oncology Trial Design FAQs & Common IssuesOptimizing Oncology Trial Design FAQs & Common Issues
Optimizing Oncology Trial Design FAQs & Common Issues
 
Day 3 SPSS
Day 3 SPSSDay 3 SPSS
Day 3 SPSS
 
Extending A Trial’s Design Case Studies Of Dealing With Study Design Issues
Extending A Trial’s Design Case Studies Of Dealing With Study Design IssuesExtending A Trial’s Design Case Studies Of Dealing With Study Design Issues
Extending A Trial’s Design Case Studies Of Dealing With Study Design Issues
 
Hypo
HypoHypo
Hypo
 
2020 trends in biostatistics what you should know about study design - slid...
2020 trends in biostatistics   what you should know about study design - slid...2020 trends in biostatistics   what you should know about study design - slid...
2020 trends in biostatistics what you should know about study design - slid...
 
Analyzing experimental research data
Analyzing experimental research dataAnalyzing experimental research data
Analyzing experimental research data
 
Sudhakar singh meta analysis
Sudhakar singh meta analysisSudhakar singh meta analysis
Sudhakar singh meta analysis
 
Basics statistics
Basics statistics Basics statistics
Basics statistics
 

PPOS design

  • 2. "One important idea is that science is a means whereby learning is achieved, not by mere theretical speculation on the one hand, nor by the undirected accumulation of practical facts on the other, but rather by a motivated iteration between theory and practice." (George E. P. Box)
  • 3. Outline Motivation examples Selected literature reveiw PPOS design of a pilot trial PPOS design of futility IA of a con…rmatory trial
  • 4. Motivation Example1: Pilot Trial Design Phase II trial to compare PFS between exp and control Randomization ratio: 1: 1 Traditional design – Type I error rate: 0.2 – Power=0.7 to detect a HR=0.75 – Event size: 90
  • 5. Motivation Example1: Pilot Trial Design Pilot trial (e.g. phase II) results are usually not the …nal goal. Pilot trial usually provides evidence to support a Go/No Go decision for a bigger future (e.g. phase III) trial. Proposal: design a pilot trial based on predictive probability of success (PPOS) in future con…rmatory trial.
  • 6. Motivation Example 2: futility interim of a con…rmatory trial A phase 3 trial to compare PFS between exp and control arms Number of events at …nal analysis: 500 Type I error rate (one sided) = 0.025 Question: how to place an non-binding futility IA Traditional design: beta spending Proposal: design based on PPOS in the …nal analysis
  • 7. PPOS is a Variable!!! Conditional power: probability of observing future statistical signi…cance assuming the parameter equals a speci…c value Predictive power: probability of observing future statistical signi…cance assuming the parameter has a speci…c distribution Predictive probability of success (PPOS): probability of future success assuming the parameter has a speci…c distribution
  • 8. Types of PPOS Type of data: binary, normal, time to event Relationship between the trial providing data and the trial to be predicted – cross trial: using data from one trial to predict another independent trial – within trial: using IA to predict …nal anlaysis (include IA data) Relationship between the end point providing information and the end point to be predicted (Tang, 2015) – 1:1 Use 1 end point to predict same end point e.g. use PFS at IA to predict PFS at …nal analysis – 1:1 Use 1 end point to predict di¤erent end point e.g. use short term end point in a pilot trial to predict a long term end point in a con…rmatory trial
  • 9. Seleted Literature Review Spiegelhalter et al (1986) compared conditional power and predictive power. Speigelhalter et al (1986) evaluated sample size using predictive probabilities. – Predictive probability of success – Predictive probability of failure – Predictive probability of non-commitment
  • 10. Selected Literature Review Stallard, Whitehead, and Cleall (2005) used Bayesian predictive probability of suc- cess for a Go/No Go decision to phase III based on data from phase II. The method predicts the success of OS in the phase 3 trial using response and PFS data from phase 2 trail.
  • 11. Selected Literature Review Lee and Liu (2008) proposed a two-stage Bayesian phase II design based on predic- tive probability of success for binary end point single arm trial. The method …nds the cuto¤ for PPOS by minimizing the maximum sample size (Nmax) while meeting type I error rate and power requirement.
  • 12. Selected Literature Review Tang and Dey (2011) in a cross trial setting for time to event end point – Design criteria: PPOS and false positive rate – Di¤erence between pilot and con…rmatory trial design are accounted by cross trial variability Wang et al (2013) in a cross-trial setting for time to event data – Prediction of combination treatment e¢ cacy based on single agent data – Prediction of future trial with di¤erent end point from pilot trial – PPOS calculated using simulation
  • 13. Selected Literature Review Berry (2006) covered many real life application of PPOS – Monitoring trial: In one Herceptin trial without IA, DSMB requested PPOS and overode the protocol to terminate the trial. – Adaptive assignment of patients in dose …nding trials Brannath et al (2009) used PPOS as a facility for population selection in adaptive design – Predictive probability and posterior probability are used for decision making. – Cuto¤ determined by simulated operation characteristic
  • 14. Common Issues In Current Practice Interpretation of PPOS based on point estimate alone PPOS cuto¤ determined by OC Mixed use of predictive probability of success and posterior probability of success
  • 15. Cross Trial PPOS and Pilot Trial Design
  • 16. Cross Trial PPOS End point: time to event, same in pilot trial and con…rmatory trial Parameter of interest: ln (HR) PPOS: predictive probability of observing a successful HR (e.g. clinical meaningful) in the future trial given the observed HR in the pilot trial. ^ is the estimated ln (HR) ^j ~N ; 2 = 1= (r (1 r) d) where r is the randomization ratio, d is the number of events
  • 17. Cross Trial PPOS Assume a Gaussian prior ln (HR) = ~N 0; 2 0 = 1= (r (1 r) d0) ^1 is the estimated ln (HR) in a pilot trial ^1j ~N ; 2 1 = 1= (r (1 r) d1)
  • 18. Cross Trial PPOS The posterior distribution is j^1~N ^1 + (1 ) 0; 2 0 (1 ) or where = 1 + 2 1 2 0 1 = 2 0 2 0+ 2 1
  • 19. Cross Trial PPOS ^2 is the estimated ln (HR) in future con…rmatory trial ^2j ~N ; 2 2 = 1= (r (1 r) d2) The predictive distribution of ^2j^1 is ^2j^1~N ^1 + (1 ) 0; 2 0 (1 ) + 2 2 PPOS = ( [ ^1+(1 ) 0]q 2 0(1 )+ 2 2 )
  • 20. Motivation Exampe 1 Input for PPOS calculation Prior information – Non-informative prior: prior variance = in…nity (equivalent to 0 event) Envisioned phase III (matching pilot design): 500 events Success criteria: HR 0:75 (clinical meaningful) PPOS in 2 di¤erent designs Event size = 90;PPOS = 0:30 if observed HR = 0:846 in phase II Event size = 40;PPOS = 0:30 if observed HR = 0:889 in phase II
  • 21. PPOS Credible Interval The information supporting PPOS calculation is summarized in the posterior dis- tribution. (1 =2)100% percentile of PPOS = ( [ =2 100% percentile of j^1]q 2 0(1 )+ 2 2 )
  • 22. PPOS Decision Rule f PPOS(d1; HR1) PPOS1 (1 =2) 100th PPOS percentile (d1; HR1) PPOS2 for No Go decision
  • 23. PPOS Optimal Design Finding the optimal design is to …nd the solution to the following equations with respect to d1 and cuto¤ HR1 f PPOS(d1; cut:HR1) = PPOS1 (1 =2) 100th PPOS percentile (d1; cut:HR1) = PPOS2
  • 24. Motivation Example1: PPOS design f PPOS(d1; HR1) 30% 80th PPOS percentile (d1; HR1) 60% for No Go decision Optimal design: d1 = 86;cuto¤ HR = 0:848
  • 25. Motivation Example1: PPOS optimal design Contour lines: black (PPOS), red (80th percentile); Intersection: optimal design
  • 26. Within Trial PPOS and Futility Interim Design
  • 27. Within Trial PPOS Consider a randomized phase 3 trial wiht time to event end point. Parameter of interest is log(HR) PPOS: probability of observing a successful HR at the end of the trial given the data at interim analysis. PPOS = 0 @ !1z(t) !2 = p r(1 r)(dmax d) h '^(t)+(1 ') 0 i q 2 0(1 ')+ 2 2 1 A (Tang, 2014)
  • 28. PPOS Decision Rule We may mandate that if the following 2 conditions are satis…ed, then futility will be declared. f PPOS PPOS1 (1 =2) 100th PPOS percentile PPOS2
  • 29. PPOS Optimal Design Finding the optimal futility interim design is to …nd the solution of the following equations with respect to timing of the analysis t and cuto¤ HR at IA. f PPOS(t; HR:IA) = PPOS1 (1 =2) 100th PPOS percentile (t; HR:IA) = PPOS2
  • 30. Motivation Example 2 Prior variance = in…nity (equivalent to 0 prior events) Success criteria: observing clinically meaningful results (HR < 0:75) at …nal analy- sis Final analysis at 500 events Randomization ratio 1:1
  • 31. Optimal futility interim design When the following 2 conditions are satis…ed, futility will be declared. f PPOS(t; HR:IA) 20% 80th PPOS percentile (t; HR:IA) 40% Optimal futility IA design:t = 0:511; d1 = 256 and cuto¤ HR at IA to be 0:807
  • 32. Take home message The success criteria in PPOS is not restricted to statistical signi…cance. Interpretation of PPOS should be based on both point estimate and CI. PPOS designs have intuitive interpretation. PPOS calculation involves subjective choices. Some analytical methods have been developed to calculate PPOS and CI.
  • 33. Reference Berry D. Bayesian clinical trials. Nature reviews, 2006, 5: 27-36. Brannath W. Zuber E. Branson M. Bretz F. Gallo P. Posch M and Racine-Poon A. Con…rmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine, 2009, 28, 1445-1463. Johns D and Anderson J, Use of predictive probabilities in phase II and phase III clinical trials. Journal of Biopharmaceutical Statistics. 1999; 9(1): 67-79. Lee J and Liu D, A predictive probability design for phase II cancer clinical trials. Clinical Trials. 2008; 5:93-106. Spiegelhalter, D. J. and Freeman L. S. A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. Statistics Medicin, 5: 1-13, 1986. Spiegelhalter, D. J., Freedman, L. S., Blackburn, P. R. (1986). Monitoring clinical trials: conditional or predictive power. Controlled Clinical Trials 7:8–17.
  • 34. Reference Stallard N, Whitehead J and Cleall S, Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts. Pharmaceutical Statistics, 2005, 4: 119-128. Tang, Z. Dey, J. (2011). Bayesian PPOS design for clinical trials. PaSIPHIC anual meeting. Tang, Z. (2014). Optimal futility interim design: a predictive probability approach with time to event ene point. Journal of Biopharmaceutical Statistics. DOI: 10.1080/10543406.201 Tang, Z. (2015). Pilot trial design: a predictive probability of success approach with time to event end points. Statistical Methods in Medical Research (under review). Wang, Y. Fu, H. Kulkarni, P. and Kaiser, C. (2013). Evaluating and utilizing probability of study success in clinical development. Clinical Trials, 10, 407-413.